Cybin Inc (CYBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cybin Inc (CYBN) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-31.95 Million ≈ $-23.11 Million USD) by net assets (CA$273.93 Million ≈ $198.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cybin Inc stock valuation for the company's overall valuation and market capitalisation.
Cybin Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Cybin Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cybin Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cybin Inc ranked by their cash flow conversion efficiency. See Cybin Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Micro Contact Solution Co. Ltd
KQ:098120
|
0.033x |
|
G Willi-Food International Ltd
TA:WILC
|
0.026x |
|
Bourse Direct SA
PA:BSD
|
0.130x |
|
Cadiz Inc
NASDAQ:CDZI
|
-1.425x |
|
Nak Sealing Technologies Corp
TW:9942
|
0.022x |
|
Materialise NV
F:06MA
|
0.041x |
|
Promotora Ambiental S.A.B. de C.V
MX:PASAB
|
0.100x |
|
RMR Group Inc
NASDAQ:RMR
|
0.072x |
Annual Cash Flow Conversion Efficiency for Cybin Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Cybin Inc from 2020 to 2025. View CYBN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$237.20 Million ≈ $171.59 Million |
CA$-101.30 Million ≈ $-73.28 Million |
-0.427x | -80.93% |
| 2024-03-31 | CA$291.93 Million ≈ $211.18 Million |
CA$-68.91 Million ≈ $-49.85 Million |
-0.236x | +76.00% |
| 2023-03-31 | CA$48.23 Million ≈ $34.89 Million |
CA$-47.43 Million ≈ $-34.31 Million |
-0.983x | -65.65% |
| 2022-03-31 | CA$76.16 Million ≈ $55.09 Million |
CA$-45.21 Million ≈ $-32.70 Million |
-0.594x | -168.68% |
| 2021-03-31 | CA$86.12 Million ≈ $62.30 Million |
CA$-19.03 Million ≈ $-13.76 Million |
-0.221x | +76.90% |
| 2020-03-31 | CA$1.45 Million ≈ $1.05 Million |
CA$-1.38 Million ≈ $-1.00 Million |
-0.956x | -- |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more